Heather Wakelee

Publications

• Lung cancer incidence in never smokers. Wakelee HA, Chang ET, Gomez SL, Keegan TH, Feskanich D, Clarke CA, Holmberg L, Yong LC, Kolonel LN, Gould MK, West DW. J Clin Oncol. 2007; 25 (5): 472-8
• Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. Hsu JY, Wakelee HA. BioDrugs. 2009; 23 (5): 289-304
• Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, Ullrich SJ, Fisher GA, Tolcher AW. Ann Oncol. 2009
• Osteoblastic bone flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy. Krupitskaya Y, Eslamy HK, Nguyen DD, Kumar A, Wakelee HA. J Thorac Oncol. 2009; 4 (3): 429-31
• Uncovering disparities in survival after non-small-cell lung cancer among Asian/Pacific Islander ethnic populations in California. Chang ET, Shema SJ, Wakelee HA, Clarke CA, Gomez SL. Cancer Epidemiol Biomarkers Prev. 2009; 18 (8): 2248-55
• Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer. Wakelee H, Kernstine K, Vokes E, Schiller J, Baas P, Saijo N, Adjei A, Goss G, Gaspar L, Gandara DR, Choy H, Putnam JB. Clin Lung Cancer. 2008; 9 (6): 346-51
• Sex differences in lung-cancer susceptibility: a smoke screen? Wakelee HA, Gomez SL, Chang ET. Lancet Oncol. 2008; 9 (7): 609-10
• Lung cancer presenting with amegakaryocytic thrombocytopenia. Witteles WH, Schrier SL, Wakelee HA. J Clin Oncol. 2008; 26 (7): 1171-4
• Adjuvant chemotherapy for resected non-small cell lung cancer. Wakelee H, Chhatwani L. Semin Thorac Cardiovasc Surg. 2008; 20 (3): 198-203
• Antibodies to vascular endothelial growth factor in non-small cell lung cancer. Wakelee H, J Thorac Oncol. 2008; 3 (6 Suppl 2): S113-8
• Complications of ablative therapies in lung cancer. Padda S, Kothary N, Donington J, Cannon W, Loo BW, Kee S, Wakelee H. Clin Lung Cancer. 2008; 9 (2): 122-6
• Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? Langer CJ, Wakelee H, Schiller J, Choy H, Shepherd F, Vokes EE, Adjei AA, Baas P, Saijo N, Gandara DR. Clin Lung Cancer. 2008; 9 (2): 85-91
• Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer. Wakelee H, Langer C, Vokes E, Schiller J, Baas P, Saijo N, Adjei A, Shepherd F, Choy H, Gandara DR. Clin Lung Cancer. 2008; 9 (1): 9-15
• Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. Lynch TJ, Blumenschein GR, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. J Thorac Oncol. 2008; 3 (6 Suppl 2): S107-12
• Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease. Wakelee H, Dubey S, Gandara D. Oncologist. 2007; 12 (3): 331-7
• Adjuvant chemotherapy of stage I non-small cell lung cancer in North America. Gandara DR, Wakelee H, Calhoun R, Jablons D. J Thorac Oncol. 2007; 2 (7 Suppl 3): S125-7
• Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Cabebe E, Wakelee H. Curr Treat Options Oncol. 2007; 8 (1): 15-27
• Metabolic tumor burden predicts for disease progression and death in lung cancer. Lee P, Weerasuriya DK, Lavori PW, Quon A, Hara W, Maxim PG, Le QT, Wakelee HA, Donington JS, Graves EE, Loo BW. Int J Radiat Oncol Biol Phys. 2007; 69 (2): 328-33
• Sunitinib: a newly approved small-molecule inhibitor of angiogenesis. Cabebe E, Wakelee H. Drugs Today (Barc). 2006; 42 (6): 387-98
• A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung carcinoma. Roy MS, Le QT, Donington JS, Wakelee HA. Clin Lung Cancer. 2006; 8 (2): 146-8
• An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O'Byrne KJ, Koong AC, Giaccia AJ. Clin Cancer Res. 2006; 12 (5): 1507-14
• Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. Le QT, Loo BW, Ho A, Cotrutz C, Koong AC, Wakelee H, Kee ST, Constantinescu D, Whyte RI, Donington J. J Thorac Oncol. 2006; 1 (8): 802-9
• Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, Johnson DH. J Thorac Oncol. 2006; 1 (5): 441-6
• Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial. Wakelee HA, Schiller JH, Gandara DR. Clin Lung Cancer. 2006; 8 (1): 18-21
• Second- and third-line treatments in non-small cell lung cancer. Kumar A, Wakelee H. Curr Treat Options Oncol. 2006; 7 (1): 37-49
• Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Wakelee HA, Bernardo P, Johnson DH, Schiller JH. Cancer. 2006; 106 (10): 2208-17
• Lung cancer in women: exploring sex differences in susceptibility, biology, and therapeutic response. Donington JS, Le QT, Wakelee HA. Clin Lung Cancer. 2006; 8 (1): 22-9
• Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors. Wakelee HA, Sikic BI. Clin Lung Cancer. 2005: 7 Suppl 1 S6-12
• Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI. J Clin Oncol. 2005; 23 (24): 5613-9
• Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. Wakelee HA, Schiller JH. Clin Lung Cancer. 2005: 7 Suppl 1 S31-8
• Optimizing first-line treatment options for patients with advanced NSCLC. Wakelee H, Belani CP. Oncologist. 2005: 10 Suppl 3 1-10
• Docetaxel in advanced non-small cell lung cancer. Wakelee H, Ramalingam S, Belani CP. Expert Rev Anticancer Ther. 2005; 5 (1): 13-24
• Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. Wakelee HA, Stephenson P, Keller SM, Wagner H, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH. Lung Cancer. 2005; 48 (3): 389-97
• A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer. Wakelee H, Fisher GA. Invest New Drugs. 2005; 23 (3): 241-2
• Novel approaches for the treatment of small cell lung cancer. Wakelee H, Kelly K. Hematol Oncol Clin North Am. 2004; 18 (2): 499-518
• Delta F508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. Haws CM, Nepomuceno IB, Krouse ME, Wakelee H, Law T, Xia Y, Nguyen H, Wine JJ. Am J Physiol. 1996; 270 (5 Pt 1): C1544-55